Welcome, AI enthusiasts!

Discover how to quickly draft winning RFPs, stay ahead of new AI security threats, and explore cool tools for automating your marketing. Plus, learn about a new AI that can detect diseases just by analyzing coughs.

In today’s Generative AI Newsletter:  

• Discover, Learn, Grow and Invest with Generative AI

• AI Assistant for Drafting RFP Response in Minutes

• New and Serious Threat: The Rise of Prompt Injection Attacks

• AI Model Revolutionizes Disease Detection Through Cough Analysis

• GPT-4 Turbo Fine-Tuning Now Accessible to All Developers on Paid Tiers via OpenAI Dashboard

• 5 AI Marketing Automation Tools

Discover, Learn, Grow and Invest with Generative AI

Generative AI, the world's largest and fastest-growing AI community, is opening up unique investment opportunities. As we continue to drive AI innovation, we're offering early investors a chance to reap substantial rewards.

Why Invest Now?

• Time-Based Bonuses: Invest by October 20 and earn up to 25% bonus shares.

With the AI industry booming and our community expanding by 300,000 new followers each month, there's never been a better time to get involved.

🔗 Invest today and maximize your returns with these exclusive bonuses.

AI Assistant for Drafting RFP Response in Minutes

Say goodbye to months of tedious effort spent sifting through RFPs to identify the right opportunities and crafting winning responses.

Wand’s innovative AI agent easily extracts key RFP requirements, analyzes their relevance to your business, and quickly drafts tailored responses.

⚡️Manages multiple RFPs simultaneously and meets tight deadlines without compromising quality.

⚡️Meticulously extracts and verifies RFP details, reducing errors and ensuring fully accurate and compliant responses.

⚡️Handles a high volume of challenging RFPs with ease and provides intelligent support for even the most complex queries.

Get the Wand AI agent for Free to Win More RFPs 🏆

New and Serious Threat: The Rise of Prompt Injection Attacks

For instance, a hacker could trick a chatbot into revealing sensitive information by inputting a simple command like, "Ignore all previous instructions."

Current defenses are not foolproof, creating a vital opportunity for startups to innovate and secure AI systems. As we integrate AI deeper into our lives, proactive security measures are essential.

For a deeper dive into prompt injection and its implications, check out the full article on Medium.

AI Model Revolutionizes Disease Detection Through Cough Analysis

The latest innovation by Google Research, Health Acoustic Representations (HeAR), is a bioacoustic AI model designed to help researchers tap into the rich information hidden in the sounds our bodies make.

HeAR has been trained on an immense dataset of 300 million audio samples, with 100 million focused solely on coughs.

This allows the model to recognize patterns that may signal health issues, potentially even before other symptoms appear.

GPT-4 Turbo Fine-Tuning Now Accessible to All Developers on Paid Tiers via OpenAI Dashboard

Training costs are set at $25 per million tokens, with inference priced at $3.75 per million input tokens and $15 per million output tokens.

To kick off the new feature, OpenAI is offering up to 1 million tokens per day for free to use on fine-tuning GPT-4o.

This is a great opportunity for developers to experiment with custom models without the usual costs.

🤖 5 AI Marketing Automation Tools

Jasper AI - Helps you write content quickly and easily using AI.

Sprout Social - Helps you manage and automate your social media posts and analyze performance.

Leonardo AI - Helps you create images and designs automatically with AI.

SocialBee - Helps automate social media posting and grow your audience.

FastTony - Provides AI tools for automating and optimizing Facebook and Instagram ads.

🚀 Contact us to reach 6M+ of tech professionals, investors, engineers, managers, and business owners worldwide.

🌟 Sign up for the first AI Hub in the world.

📲 Our Socials

^{_{Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.
DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 4000 Eagle Point Corporate Drive, Suite 950, Birmingham, AL 35242, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA's BrokerCheck. DealMaker Securities LLC does not make investment recommendations. DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer. DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor's documentation for this investment. DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing. DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself. Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.}}